ANAVEX1066 / Anavex - LARVOL DELTA

ANAVEX LIFE SCIENCES CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) (Market Screener) - “We also own two issued U.S. patents related to ANAVEX®1066. The first of these two patents claims methods for treating or preventing pain using (+) ANAVEX®1066 isomer. The second patent claims methods for treating or preventing pain using (-) ANAVEX®1066 isomer. Both patents are expected to expire in November 2036, absent any patent term extension for regulatory delays.”

Patent • CNS Disorders • Pain